For the quarter ending 2026-03-31, ACONW had $6,989,187 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,853,575 | -1,889,142 | -1,706,294 | -3,638,193 |
| Depreciation and amortization | 60,909 | 61,313 | 58,364 | 107,729 |
| Amortization of deferred issuance costs | - | 0 | 0 | 0 |
| Loss on exchange of debt | - | 0 | 0 | 0 |
| Loss on extinguishment of debt | - | 0 | 0 | 0 |
| Share-based compensation | 4,694 | 4,365 | 16,746 | 84,257 |
| Amendment of warrants | 0 | 0 | 0 | 48,087 |
| Non-cash settlements | 0 | 0 | 0 | 58,272 |
| Change in fair value related to warrants and derivative | -18 | -39 | -1 | -11,766 |
| Non-cash interest related to bridge funding | - | 0 | 0 | - |
| Non-cash expenses related to equity line agreement | - | 0 | - | - |
| Accounts receivable | 10,903 | -2,338 | 11,097 | 2,595 |
| Prepaids and other current assets | -20,243 | -180,157 | -68,011 | 232,111 |
| Accounts payable | 242,195 | 15,366 | 54,230 | -268,237 |
| Accrued and other liabilities | -105,390 | -1,796 | 359,669 | -521,837 |
| Note payable, net of discount | - | - | 0 | 0 |
| Net cash used in operating activities | -2,641,845 | -1,627,438 | -1,160,372 | -4,376,394 |
| Issuance of common stock and warrants related to public offering, net deductions | - | - | 0 | - |
| Fixed assets | - | 13,726 | 7,321 | 481 |
| Proceeds from common stock and warrant rega+ offering | - | 0 | 0 | - |
| Intangible assets patents | 49,345 | 27,735 | 32,829 | 121,810 |
| Proceeds from sales of c-series preferred stock and warrants | - | - | 0 | - |
| Net cash used in investing activities | -49,345 | -41,461 | -40,151 | -122,290 |
| Proceeds from equity line | - | 0 | 0 | 0 |
| Public offering of common stock and warrants | 0 | 0 | 0 | 14,554,545 |
| Registered direct offerings of common stock | 1,036,000 | 535,041 | 0 | 5,167,927 |
| Proceeds from direct offering of prefunded warrants | 9,323,982 | 1,972,957 | - | - |
| Proceeds from sale of preferred stock | - | 0 | - | - |
| Proceeds from sale of common stock and warrants, atm | - | 0 | - | - |
| Common stock cash issuance costs | 679,605 | 164,646 | 283,798 | 1,959,643 |
| Repayment of promissory notes | - | 0 | 0 | 0 |
| Bridge fund cash issuance costs | - | - | 0 | 0 |
| Equity line cash issuance costs | - | 0 | - | - |
| Exercise of series c warrants | 0 | 0 | 0 | 336,441 |
| Preferred stock cash issuance costs | - | 0 | 0 | - |
| Redemption of series b preferred stock | 0 | 0 | 0 | 1,213,590 |
| Net cash provided by financing activities | 9,680,377 | 2,343,352 | -283,798 | 16,885,680 |
| Net increase (decrease) in cash and cash equivalents | 6,989,187 | 674,453 | -1,484,321 | 12,386,996 |
| Cash, cash equivalents and restricted cash, beginning of period | 12,040,789 | 11,366,336 | 463,661 | - |
| Cash, cash equivalents and restricted cash, end of period | 19,029,976 | 12,040,789 | 11,366,336 | - |
Aclarion, Inc. (ACONW)
Aclarion, Inc. (ACONW)